Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
https://www.stockwatch.com/News/Item.aspx?bid=U-C5728-U%3aGBLX-20180108&symbol=GBLX®ion=U
GB Sciences Is Maximizing the Production of Critical Medical Components from Specific Cannabis Strains
2018-01-08 05:30 ET - News Release
GB Sciences Is Maximizing the Production of Critical Medical Components from Specific Cannabis Strains
Effective medicines start with quality ingredients. GB Sciences has developed controlled growth environments and methods to amplify the yield of important raw materials for its medical formulations.
Canada NewsWire
LAS VEGAS, Dec. 8, 2018
LAS VEGAS, Dec. 8, 2018 /CNW/ -- GB Sciences, Inc. (OTCQB: GBLX) currently markets both medical and adult use cannabis products in Nevada under the respected Cultivation Labs brand. The Company has selected and nurtured several cannabis strains that are scoring some of the highest testing lab results seen in the Nevada market, according to the chemoprofile test results from DigiPath Labs.
But this is only one half of the story. By maximizing the production of critical raw materials that can only be derived from the cannabis plant, GB Sciences is able to provide the base materials for their proprietary cannabis-based medical formulations. This breakthrough places cannabis-based medical formulations on a level playing field with traditional medical formulations when it comes to patient studies and clinical trials; a task that, until now, has proven extremely difficult industry-wide.
John Poss, Chairman and CEO stated, "Cannabis-based formulations can now move past anecdotal evidence and instead provide hard, verifiable data to prove safety and efficacy. This changes everything. This is the basis of real medicine."
The latest proven strain in GB Sciences' ongoing research is WiFi OG, a 60% sativa dominant hybrid. The tissue propagation unit regenerated the strain using the GB Sciences' proprietary tissue culture process to get a proper volume of test plants to facilitate research. This process not only ensures zero mold or bacteria in the mother plants, but also allows GB Sciences to create libraries of healthy strains.
The Cultivation Labs unit then placed the strain into their precision controlled growing environments and optimized the strain-specific growing conditions, enhancing the yield of critical components useful in both the recreational market and as the ingredients in the proprietary medical formulations.
"GB Sciences has clearly established that plant husbandry is a key variable that can be exploited to maximize the inherent genetic potential in a given cannabis strain for an enhanced phenotypic outcome as observed in chemoprofiles," shared Digipath's Chief Science Officer Cindy Orser, Ph.D.
"It's no surprise that the test results get better over time as we dial-in the environmental conditions to meet the specific needs of each strain", said Kevin Kuethe, COO of GB Sciences. "We are now able to modify the environmental controls to allow each specific strain to maximize the production of these key cannabinoids and terpenes."
Mr. Poss concluded, "GB Sciences was founded on the belief that all people who consume cannabis, regardless of the labels of medical or adult use, are patients of one sort or another. And we could find no one in the industry who had taken the time or made the effort to solve the most basic issue involved in making real medicine... creating pure, trusted, and abundant base ingredients for their medical formulations. Without that element, all the evidence is purely anecdotal. So, this is where we focused our efforts. Research is in our corporate DNA, and it's beginning to pay off."
About GB Sciences, Inc.
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
Contact Information
GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118
866-721-0297, or
Tom Arcuragi, SR VP Marketing, tom@gbsciences.com, http://gbsciences.com
View original content with multimedia:http://www.prnewswire.com/news-releases/gb-sciences-is-maximizing-the-production-of-critical-medical-components-from-specific-cannabis-strains-300578642.html
SOURCE GB Sciences, Inc.
View original content with multimedia: http://www.newswire.ca/en/releases/archive/January2018/08/c5728.html
© 2018 Canjex Publishing Ltd. All rights reserved.GB Sciences Is Maximizing the Production of Critical Medical Components from Specific Cannabis Strains
2018-01-08 05:30 ET - News Release
GB Sciences Is Maximizing the Production of Critical Medical Components from Specific Cannabis Strains
Effective medicines start with quality ingredients. GB Sciences has developed controlled growth environments and methods to amplify the yield of important raw materials for its medical formulations.
Canada NewsWire
LAS VEGAS, Dec. 8, 2018
LAS VEGAS, Dec. 8, 2018 /CNW/ -- GB Sciences, Inc. (OTCQB: GBLX) currently markets both medical and adult use cannabis products in Nevada under the respected Cultivation Labs brand. The Company has selected and nurtured several cannabis strains that are scoring some of the highest testing lab results seen in the Nevada market, according to the chemoprofile test results from DigiPath Labs.
But this is only one half of the story. By maximizing the production of critical raw materials that can only be derived from the cannabis plant, GB Sciences is able to provide the base materials for their proprietary cannabis-based medical formulations. This breakthrough places cannabis-based medical formulations on a level playing field with traditional medical formulations when it comes to patient studies and clinical trials; a task that, until now, has proven extremely difficult industry-wide.
John Poss, Chairman and CEO stated, "Cannabis-based formulations can now move past anecdotal evidence and instead provide hard, verifiable data to prove safety and efficacy. This changes everything. This is the basis of real medicine."
The latest proven strain in GB Sciences' ongoing research is WiFi OG, a 60% sativa dominant hybrid. The tissue propagation unit regenerated the strain using the GB Sciences' proprietary tissue culture process to get a proper volume of test plants to facilitate research. This process not only ensures zero mold or bacteria in the mother plants, but also allows GB Sciences to create libraries of healthy strains.
The Cultivation Labs unit then placed the strain into their precision controlled growing environments and optimized the strain-specific growing conditions, enhancing the yield of critical components useful in both the recreational market and as the ingredients in the proprietary medical formulations.
"GB Sciences has clearly established that plant husbandry is a key variable that can be exploited to maximize the inherent genetic potential in a given cannabis strain for an enhanced phenotypic outcome as observed in chemoprofiles," shared Digipath's Chief Science Officer Cindy Orser, Ph.D.
"It's no surprise that the test results get better over time as we dial-in the environmental conditions to meet the specific needs of each strain", said Kevin Kuethe, COO of GB Sciences. "We are now able to modify the environmental controls to allow each specific strain to maximize the production of these key cannabinoids and terpenes."
Mr. Poss concluded, "GB Sciences was founded on the belief that all people who consume cannabis, regardless of the labels of medical or adult use, are patients of one sort or another. And we could find no one in the industry who had taken the time or made the effort to solve the most basic issue involved in making real medicine... creating pure, trusted, and abundant base ingredients for their medical formulations. Without that element, all the evidence is purely anecdotal. So, this is where we focused our efforts. Research is in our corporate DNA, and it's beginning to pay off."
About GB Sciences, Inc.
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
Contact Information
GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118
866-721-0297, or
Tom Arcuragi, SR VP Marketing, tom@gbsciences.com, http://gbsciences.com
View original content with multimedia:http://www.prnewswire.com/news-releases/gb-sciences-is-maximizing-the-production-of-critical-medical-components-from-specific-cannabis-strains-300578642.html
SOURCE GB Sciences, Inc.
View original content with multimedia: http://www.newswire.ca/en/releases/archive/January2018/08/c5728.html
© 2018 Canjex Publishing Ltd. All rights reserved.
It seems that american stockholders would now be exposed to currency risk, the value of your holdings would fluctuate with the CAD$ Vs. US$
This Daddy needs a new vaporizer. LOL
Snoop Dog for attorney general
Sessions:
When he goes low
We get high!
When Sessions goes low
We get high! LOL
“The last time the Investment Industry Regulatory Organization of Canada (IIROC) intervened in the trading of Canadian publicly traded cannabis companies was in November 2016. Canopy Growth Corp, the first, biggest, and most valuable ACMPR-licensed grower had popped to over $17 a share on no news, and IIROC halted trading to “to ensure a fair and orderly market.”
IIROC halted stocks multiple times that day, with trading resuming on an average of about 10 minutes later in all cases.
What followed was the onset of a downward revision in valuations for all the major publicly-listed cannabis players, which culminated in a halving of the value, roughly, of the entire sector. (see chart below).
But on the last trading day of 2017, IIROC again stepped in, this time after a handful of the largest stocks had begun to sell off after spiking by as much as 20 percent that day, as traders took profits from an outstanding lift in valuations over the few previous sessions.
Is this the event that will catalyze a reversal beginning in 2018?
I think it is.
Traders and investors alike don’t like it when a regulator steps in to limit the downside or the upside to their investing. And rightly so: a free and fair marketplace must be unencumbered by government intervention unless there is strong evidence of malfeasance, corruption or manipulation.
In this case, just as in November 2016, regulators halted trading in an attempt to cool the irrational exuberance that can cause stocks to soar with little material justification. This is the essence of speculation. If you’re going to limit my upside without limiting my downside, you have just undermined the rationale for any risk/reward model.
It’s irresponsible, in my opinion, and constitutes regulatory overreach.
But the reasons for my conviction that we have just seen the top in cannabis stocks for the near future is more fundamental.
The Canadian government has stipulated that it will seek to triple the number of ACMPR licensees before the end of 2018, which suggests that there could be another 160 licenses granted in the next 12 months.
If you consider that the funded growing capacity of the 20+ publicly traded cannabis growers is above 2 million kilograms per year according to a rough survey of their financials, and that the most optimistic demand projection for the next 12 months is no more than 750,000 kilograms (including both medical users and assuming all illegally sourced recreational consumption), it is clear that we have an imminent supply glut.
Analysts from the investment banks are of course expected to publish wildly optimistic numbers – licensed broker dealers are the only ones actually allowed to do so. But if you consider, for a moment, what might be the funded growing capacity of the over 50 non-public ACMPR growers (and therefore, not publicly reported), you can see there might be cause for a little bit of caution.
But caution, it would appear, is not in the vocabulary of Health Canada’s licensing thought process.
Already, institutional investors in Canada are telling me that the value of a license is approaching zero with no funded growing capacity. What is it worth with 200% more licenses?
There are mitigating factors to consider.
Media stories promoting the idea that there will be a global trade in cannabis and related products is likely largely responsible for the year end feeding frenzy in cannabis stocks. And there is likely some genuine demand momentum in that narrative. But which of the countries just now adopting legalization measures won’t ultimately seek to capture the economic benefit of the nascent industry by growing it themselves in the end? The export premium should be short-lived, at best.
And bear in mind; at the end of the day, cannabis is commodity with a slightly more sophisticated range of growing environment variability than canola oil or wheat. But not a whole hell of a lot.
Overall, I think the valuation picture in Canadian cannabis pubcos could be maxed out, in the case of the largest ones. I think investors will be able to score wins on newly listed, well managed and funded ACMPR growers in 2018. At least until the supply glut starts showing up on the balance sheets of the majors.
But on the bright side, California – the world’s largest cannabis market – goes legal recreationally tomorrow. And there are a few Canadian-listed companies who are poised to benefit from that evolution.”
“The last time the Investment Industry Regulatory Organization of Canada (IIROC) intervened in the trading of Canadian publicly traded cannabis companies was in November 2016. Canopy Growth Corp, the first, biggest, and most valuable ACMPR-licensed grower had popped to over $17 a share on no news, and IIROC halted trading to “to ensure a fair and orderly market.”
IIROC halted stocks multiple times that day, with trading resuming on an average of about 10 minutes later in all cases.
What followed was the onset of a downward revision in valuations for all the major publicly-listed cannabis players, which culminated in a halving of the value, roughly, of the entire sector. (see chart below).
But on the last trading day of 2017, IIROC again stepped in, this time after a handful of the largest stocks had begun to sell off after spiking by as much as 20 percent that day, as traders took profits from an outstanding lift in valuations over the few previous sessions.
Is this the event that will catalyze a reversal beginning in 2018?
I think it is.
Traders and investors alike don’t like it when a regulator steps in to limit the downside or the upside to their investing. And rightly so: a free and fair marketplace must be unencumbered by government intervention unless there is strong evidence of malfeasance, corruption or manipulation.
In this case, just as in November 2016, regulators halted trading in an attempt to cool the irrational exuberance that can cause stocks to soar with little material justification. This is the essence of speculation. If you’re going to limit my upside without limiting my downside, you have just undermined the rationale for any risk/reward model.
It’s irresponsible, in my opinion, and constitutes regulatory overreach.
But the reasons for my conviction that we have just seen the top in cannabis stocks for the near future is more fundamental.
The Canadian government has stipulated that it will seek to triple the number of ACMPR licensees before the end of 2018, which suggests that there could be another 160 licenses granted in the next 12 months.
If you consider that the funded growing capacity of the 20+ publicly traded cannabis growers is above 2 million kilograms per year according to a rough survey of their financials, and that the most optimistic demand projection for the next 12 months is no more than 750,000 kilograms (including both medical users and assuming all illegally sourced recreational consumption), it is clear that we have an imminent supply glut.
Analysts from the investment banks are of course expected to publish wildly optimistic numbers – licensed broker dealers are the only ones actually allowed to do so. But if you consider, for a moment, what might be the funded growing capacity of the over 50 non-public ACMPR growers (and therefore, not publicly reported), you can see there might be cause for a little bit of caution.
But caution, it would appear, is not in the vocabulary of Health Canada’s licensing thought process.
Already, institutional investors in Canada are telling me that the value of a license is approaching zero with no funded growing capacity. What is it worth with 200% more licenses?
There are mitigating factors to consider.
Media stories promoting the idea that there will be a global trade in cannabis and related products is likely largely responsible for the year end feeding frenzy in cannabis stocks. And there is likely some genuine demand momentum in that narrative. But which of the countries just now adopting legalization measures won’t ultimately seek to capture the economic benefit of the nascent industry by growing it themselves in the end? The export premium should be short-lived, at best.
And bear in mind; at the end of the day, cannabis is commodity with a slightly more sophisticated range of growing environment variability than canola oil or wheat. But not a whole hell of a lot.
Overall, I think the valuation picture in Canadian cannabis pubcos could be maxed out, in the case of the largest ones. I think investors will be able to score wins on newly listed, well managed and funded ACMPR growers in 2018. At least until the supply glut starts showing up on the balance sheets of the majors.
But on the bright side, California – the world’s largest cannabis market – goes legal recreationally tomorrow. And there are a few Canadian-listed companies who are poised to benefit from that evolution.”
Unbalanced. Large spreads are showing up on the Canadian side from time to time. MMs are supposed to keep the spread tight. Shouldn't be a .12 difference between bid and ask. One has to wonder if the market maker, 30 Latimer uses RBC or TD who have been having problems with their trading systems.
Yesterday's candlestick reminds me of a Saturn rocket sitting on the launchpad. 10,9,8.....
That repetitive post should be removed. AMMJ has nothing to do with that!!!
Wow! We broke out of the pennant formation in the most dramatic fashion with a huge beautiful, bullish white candlestick. Higher prices are definitely ahead.
The MJX is not buying any shares in OTC or Pink Sheet companies because of the Federal legal issues.There are however 6 other MJ ETFs racing to get listed they may not be so picky.
They don't appear to be buying shares though, they're buying MJ producers and opening retail stores.
The alpha site is a paid pumper.
MJX has said that they won't include any OTC or Pink Sheet companies because of MJ being illegal federally.
Do you have a list of insiders?
Wow! California prices are super expensive. 295-420/oz. Do they include tax?
I can buy an oz. of high-quality weed here in Canada for CDN $225 no tax street price. They won't be eliminating any black market if the prices stay that high.
Wow! Prices are super expensive. Do they include tax?
I can buy an oz. of high-quality weed here in Canada for CDN $225 no tax street price. They won't be eliminating any black market if the prices stay that high.
87,948,168 Shares Traded in December
That's 68.5% of the 128,300,000 shares outstanding!
Now, that is outstanding! And an all-time monthly record!
Happy New Year
Why would you post that story with AMMJ ticker symbol in front of it?
This guy has nothing to do with American Cannabis, are you trying to mislead people?
Just seeking alpha pumping a few of the stocks they promote by suggesting that they might be included in this fund. Do you seriously think these professionals from Blackrock are going to telegraph the stocks they are going to include before they even purchase them. You'll never know what's in this fund until it starts trading.
Where do you get the info that GRNH will be in the Emerging AgroSphere ETF Index Fund. I think this is wishful thinking for a company that does not yet have audited financials
Only 6.6 million float?
Is this accurate? We traded almost 6 million shares yesterday alone and have 128 million shares O/S. Doesn't seem possible!
My point is that the new ETF has started trading and GRNH is not included.
Hope that explains it clearly so that you can understand.
New ETF-No GRNH
https://www.msn.com/en-us/finance/markets/did-you-just-miss-the-launch-of-the-us-listed-marijuana-etf/ar-BBHnWjQ
The first trading session after Christmas is almost a quiet trading session, and the market is likely to remain quiet until after the start of 2018. The news flow from companies just is not usually that strong. One exception has been in the legalization of marijuana, where, ahead of the California legalization efforts, a U.S.-listed exchange traded fund has quietly begun trading.
ETF Managers Group LLC announced that the ETFMG Alternative Harvest ETF (NYSEAmerican: MJX) is now live and available for trading.
Quote Search
QUOTES IN THE ARTICLE
Leaf Clean Energy Ord
LEAF
=30.000.000.00%
The Scotts Miracle Gro Co
SMG
?102.97+0.42+0.41%
Impress Holdings Inc
IMB
?1.200.00-0.33%
Image Software Inc
ISOL
?0.0600+0.0299+99.34%
AdChoices
Before reading more, investors should note a message straight form the company itself -- Effective December 26, 2017 the name, underlying index, investment objective, principal investment strategy and investment policies of the Tierra XP Latin America Real Estate ETF (LARE) has changed to ETFMG Alternative Harvest ETF (MJX).
While some grouped investments have become available of late, this fund is one of the first of its kind for U.S. investors to more easily access a group of companies related to the cannabis industry. The "MJX" is designed to replicate the Prime Alternative Harvest Index. The index tracks companies which are expected to be likely beneficiaries from the increasing global acceptance of various uses of the cannabis plant.
The release noted that it will track companies expected to win in treatments from innovative medicinal breakthroughs. The company's index description was listed as follows:
The Prime Alternative Harvest Index has been created to provide investors with a product that enables them to take advantage of both event-driven news and long-term trends in the cannabis industry as well as the industries likely to be influenced by the medicinal and recreational cannabis legalization initiatives taking place in many locations globally.
The Prime Indexes website showed a breakdown of 30 companies which make up the index. Some of them are straight tobacco companies and some of these companies are ones which most investors will not have heard of. The breakdown of the index was listed as follows (name, ticker, weight):
HUABAO INTERNATIONAL HOLDINGS LTD (336) 3.08%JAPAN TOBACCO (2914) 2.76%AURORA CANNABIS INC. (ACB) 4.94%ARENA PHARMACEUTICALS INC (ARNA) 2.76%BRITISH AMERICAN TOBACCO PLC (BATS) 2.79%CARA THERAPEUTICS INC (CARA) 2.51%CANNIMED THERAPEUTICS INC. (CMED) 3.49%CORBUS PHARMACEUTICALS HOLDINGS. INC. (CRBP) 2.51%EMERALD HEALTH THERAPEUTICS (EMH) 3.07%SUPREME PHARMACEUTICALS INC. (FIRE) 2.99%GIMA TT SPA (GIMA) 2.87%GW PHARMACEUTICALS (GWPH) 5.27%IMPERIAL BRANDS PLC (IMB) 2.81%INSYS THERAPEUTICS INC. (INSY) 3.24%ISODIOL INTERNATIONAL INC. (ISOL) 2.10%MEDRELEAF CORP. (LEAF) 5.12%CRONOS GROUP INC. (MJN) 6.10%ALTRIA GROUP INC. (MO) 2.80%ORGANIGRAM HOLDINGS INC. (OGI) 2.77%PHILIP MORRIS INTERNATIONAL (PM) 2.72%SCOTTS MIRACLE (SMG) 2.80%SCANDINAVIAN TOBACCO GROUP (STG) 2.84%SCHWEITZER-MAUDUIT INTERNATIONAL INC. (SWM) 2.85%SWEDISH MATCH AB (SWMA) 2.74%TURNING POINT BRANDS INC (TPB) 2.89%CANNTRUST HOLDINGS INC. (TRST) 5.26%UNIVERSAL CORP/VA (UVV) 2.70%VECTOR GROUP LTD (VGR) 2.70%CANOPY GROWTH CORP. (WEED) 5.78%22ND CENTURY GROUP INC. (XXII) 2.74%
Investors may recall that a marijuana-focused ETF launched earlier in 2017 in Canada. That was the Horizons Marijuana Life Sciences Index ETF, and it was up over 50% locally.
The "MJX" was last seen up almost 5% at $30.18 late on Tuesday afternoon right before the closing bell. The ETF had traded 263,000 shares shortly ahead of the close.
Yes, the chart looks good. We've just broken up and out of a pennant formation, so this should signal the resumption of the uptrend. Overbought condition on RSI unwound.
C'mon Chris, drop the Bunka Bomb, let's blow this thing up!
https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aLXX-2545544&symbol=LXX®ion=C
elowna, British Columbia / TheNewswire / December 13, 2017 - Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company" or "Lexaria") a drug delivery platform innovator, announces the United States Patent and Trademark Office ("USPTO") has granted patent number 9,839,612 B2 for the use of DehydraTECH TM technology as a delivery platform for a wide variety of Active Pharmaceutical Ingredients ("APIs") including all cannabinoids including THC; fat soluble vitamins; non-steroidal anti-inflammatory pain medications ("NSAIDs"); and nicotine.
This granted patent completes the patent allowance process that was announced on October 31, 2017, and this patent grant is now final. The title of the granted patent is "Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof". This issued patent protects Lexaria's intellectual property ("IP") for the DehydraTECH TM delivery of all the active substances noted via nearly any kind of processed food or beverage as well as capsules and pills.
In one aspect a method of treating a condition is provided wherein a cannabinoid is used to treat conditions selected from the group consisting of cardiac diseases such as heart disease, ischemic infarcts, and cardiometabolic disorders, neurological diseases such as Alzheimer's disease, Parkinson's disease, schizophrenia, and Human Immunodeficiency Virus (HIV) dementia; obesity; metabolic disorders such as insulin related deficiencies and lipid profiles, hepatic diseases, diabetes, and appetite disorders; cancer chemotherapy, benign prostatic hypertrophy; irritable bowel syndrome, biliary diseases; ovarian disorders; marijuana abuse; and alcohol, opioid, nicotine or cocaine addiction.
Lexaria also continues to advance all of its additional patent applications in various countries as it levers patent success in the USA. For example, some of the Company's patent applications have recently entered the active patent investigation phase in China, the European Union, and in Canada.
"Lexaria has now locked-up the IP for its next-generation drug delivery system" said Chief Executive Officer Chris Bunka. "This ground-breaking, patented IP builds a foundation for new business opportunities in 2018 including what could be the world's first nicotine edibles for the smokeless tobacco industry, or improved new products for NSAID-derived pain management, as well as in the rapidly growing cannabis market."
Lexaria's patented DehydraTECH(TM) technology is focused on improved delivery methodologies of many commonly used API substances. As such, it provides an additional layer of effectiveness that is designed to harmonize with the intellectual property of third parties. Both patented and generic API substances can utilize Lexaria's patented technology. Lexaria's long term strategy is to partner with the world's leading firms as they deliver best-of-class products to their existing large consumer groups.
Lexaria is presently investigating and will continue to pursue additional technologies that could deliver value to its growing portfolio of patented technologies.
About Lexaria
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECHTM delivery technology. Lexaria's technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
www.lexariabioscience.com